Abstract
Neurophysiological indicators of Alzheimer’s disease include the presence of aggregated amyloid-beta (Aβ) peptide plaques and low levels of the neurotransmitter, acetylcholine, resulting in cognitive impairment. Acetylcholinesterase has been implicated in not only the aggregation of extracellular Aβ peptides through the enzyme’s peripheral anionic site, but also the hydrolysis of acetylcholine at its catalytic active site. Two components in a methanolic extract of black walnuts (Juglians nigra), gallic and ellagic acids, were found to prevent aggregation of Aβ peptides in the presence of acetylcholinesterase and to disaggregate previously formed oligomers. In addition, both compounds inhibited acetylcholinesterase activity, thus retaining higher acetylcholine concentrations. Analysis of phenolic structures related to gallic acid indicated that 1,3,5-trisubstituted phenolic rings conferred these inhibitory effects on acetylcholinesterase, and thus may provide a structural model on which to design dual inhibitors for both acetylcholinesterase catalytic activity and Aβ aggregation and disaggregation.
Keywords: Acetylcholinesterase, aggregation, amyloid-beta, phenol, dual inhibitors, Alzheimer’s disease.
Current Enzyme Inhibition
Title:Trisubstituted Phenolic Compounds as Inhibitors of Acetylcholinesterase and Amyloid Beta Aggregate Formation
Volume: 9 Issue: 1
Author(s): Caroline M. Peckels, Nathan S. Alexander, Gina N. Wilson, Joel M. Karty and Kathryn M. Matera
Affiliation:
Keywords: Acetylcholinesterase, aggregation, amyloid-beta, phenol, dual inhibitors, Alzheimer’s disease.
Abstract: Neurophysiological indicators of Alzheimer’s disease include the presence of aggregated amyloid-beta (Aβ) peptide plaques and low levels of the neurotransmitter, acetylcholine, resulting in cognitive impairment. Acetylcholinesterase has been implicated in not only the aggregation of extracellular Aβ peptides through the enzyme’s peripheral anionic site, but also the hydrolysis of acetylcholine at its catalytic active site. Two components in a methanolic extract of black walnuts (Juglians nigra), gallic and ellagic acids, were found to prevent aggregation of Aβ peptides in the presence of acetylcholinesterase and to disaggregate previously formed oligomers. In addition, both compounds inhibited acetylcholinesterase activity, thus retaining higher acetylcholine concentrations. Analysis of phenolic structures related to gallic acid indicated that 1,3,5-trisubstituted phenolic rings conferred these inhibitory effects on acetylcholinesterase, and thus may provide a structural model on which to design dual inhibitors for both acetylcholinesterase catalytic activity and Aβ aggregation and disaggregation.
Export Options
About this article
Cite this article as:
M. Peckels Caroline, S. Alexander Nathan, N. Wilson Gina, M. Karty Joel and M. Matera Kathryn, Trisubstituted Phenolic Compounds as Inhibitors of Acetylcholinesterase and Amyloid Beta Aggregate Formation, Current Enzyme Inhibition 2013; 9 (1) . https://dx.doi.org/10.2174/1573408011309010009
DOI https://dx.doi.org/10.2174/1573408011309010009 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease
Current Bioactive Compounds Neuroinflammation, Microglia and Mast Cells in the Pathophysiology of Neurocognitive Disorders: A Review
CNS & Neurological Disorders - Drug Targets Fermented Foods: Patented Approaches and Formulations for Nutritional Supplementation and Health Promotion
Recent Patents on Food, Nutrition & Agriculture Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery The Role of Apoptotic Pathways in Alzheimers Disease Neurodegeneration and Cell Death
Current Alzheimer Research Adipose Tissue: The Link Between Obesity and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Elevated Testosterone Level and Urine Scent Marking in Male 5xFAD Alzheimer Model Mice
Current Alzheimer Research Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry QSAR and Molecular Modeling Studies on a Series of Pyrrolidine Analogs Acting as BACE-1 Inhibitors
Letters in Drug Design & Discovery Caregiver Burden in Fragile X Families
Current Psychiatry Reviews Alzheimers and Dementia in the Oldest-Old: A Century of Challenges
Current Alzheimer Research Preface: Developments in Understanding of Alzheimer Disease
Current Alzheimer Research Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Genetic Association of CUGBP2 and DNMBP with Alzheimer’ s Disease in the Chinese Han Population
Current Alzheimer Research Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer’s Disease
Current Aging Science Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice
Current Psychiatry Reviews Potential Targets for the Development of Novel Antidepressants: Future Perspectives
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets